Bet v 1-specific immunoglobulin E (Bet v 1-specific IgE) (Bet v 1-specific IgE)

Bet v 1-specific immunoglobulin E (IgE) is a specialized antibody produced by the immune system in response to Bet v 1, the major allergen of birch pollen (Betula verrucosa) [UniProt P15494]. In sensitized individuals, these IgE molecules are primarily found bound to high-affinity FcεRI receptors on the surface of mast cells and basophils [NIH: StatPearls, Type I Hypersensitivity]. Upon re-exposure to birch pollen, the Bet v 1 protein cross-links these surface-bound IgE antibodies, triggering the immediate release of inflammatory mediators such as histamine and leukotrienes. This physiological response manifests clinically as allergic rhinitis, conjunctivitis, and potentially allergic asthma. Furthermore, Bet v 1-specific IgE is the primary driver of pollen-food allergy syndrome, where cross-reactivity with homologous proteins in foods like apples and hazelnuts causes oral symptoms [PubMed: PMC4655061]. Therapeutic management involves the use of monoclonal antibodies like omalizumab, which sequester IgE to prevent its interaction with receptors, or allergen immunotherapy (AIT) to induce immunological tolerance and the production of protective IgG4 antibodies [PubChem: Omalizumab; EMA: Itulazax].

Other names

Birch pollen-specific IgEAnti-Bet v 1 IgEBet v 1-sIgEImmunoglobulin E specific for Bet v 1

Neutralization of circulating IgE to prevent binding to high-affinity IgE receptors (FcεRI) on mast cells and basophils [PubChem CID 16130347], or induction of IgG4 blocking antibodies through allergen immunotherapy [PubMed: 25845398].